Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inhibikase Therapeutics (IKT) Interest Expenses (2020 - 2022)

Inhibikase Therapeutics (IKT) has 3 years of Interest Expenses data on record, last reported at $5.0 in Q1 2022.

  • On a quarterly basis, Interest Expenses fell 99.96% to $5.0 in Q1 2022 year-over-year; TTM through Dec 2022 was $5.0, a 99.97% decrease, with the full-year FY2021 number at $19923.0, down 32.24% from a year prior.
  • Interest Expenses reached $5.0 in Q1 2022 per IKT's latest filing, down from $158.0 in the prior quarter.
  • Over the last five years, Interest Expenses for IKT hit a ceiling of $11797.0 in Q1 2021 and a floor of $5.0 in Q1 2022.
  • A 3-year average of $5481.1 and a median of $7139.0 in 2020 define the central range for Interest Expenses.
  • Peak YoY movement for Interest Expenses: soared 58.88% in 2021, then plummeted 99.96% in 2022.
  • Tracing IKT's Interest Expenses over 3 years: stood at $7139.0 in 2020, then tumbled by 97.79% to $158.0 in 2021, then plummeted by 96.84% to $5.0 in 2022.
  • Business Quant data shows Interest Expenses for IKT at $5.0 in Q1 2022, $158.0 in Q4 2021, and $157.0 in Q3 2021.